ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Inhibitors in Hemophilia: Treatment Challenges in Afghanestan

1Faculty of Medical Sciences, Kateb University, Department of Clinical Biochemistry, Kabul, Afghanistan, 2Afghanistan National Charity Organization for Special Diseases (ANCOSD), Kabul, Afghanistan, 3Faculty of Medical Sciences, Tarbiat Modares University, Department of Clinical Biochemistry, Tehran, Iran, Islamic Republic of, 4Iranian Comprehensive Hemophilia Care Center (ICHCC), Tehran, Iran, Islamic Republic of, 5School of Allied Medicine, Iran University of Medical Sciences, Department of Hematology and Blood Transfusion, Tehran, Iran, Islamic Republic of, 6Biotechnology Research Centre, Pasteur Institute, Department of Molecular Medicine, Tehran, Iran, Islamic Republic of, 7Dr Zeinali's Medical Genetics Lab, Kawsar Human Genetics Research Centre, Tehran, Iran, Islamic Republic of

Abstract Number: PB0913

Meeting: ISTH 2020 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Hemophilia A (HA) is the most common severe congenital severe bleeding disorders wit high rate of morbidity and mortality. About 30% of the patients develop inhibitor against exogenous factor VIII (FVIII). Inhibitor development is the most challenging complication of the replacement therapy.

Aims: To assess prevalence of FVIII inhibitor in Afghan patients with HA.

Methods: : A total of 107 patients with HA were evaluated for inhibitors. The Nijmegen modification of the Bethesda assay was used for inhibitor assay.

Results: Of 107 patients, 11 (~10.3%) were positive for FVIII inhibitor. All patients with inhibitor had severe HA with on-demand therapy.

Conclusions: It seems that low rate of replacement therapy is the main cause of relatively low rate of inhibitor formation in Afghan patients with severe HA.

To cite this abstract in AMA style:

Mousavi SH, Mesbah-Namin SA, Jazebi M, Dorgalaeh A, Zeinali S. Inhibitors in Hemophilia: Treatment Challenges in Afghanestan [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/inhibitors-in-hemophilia-treatment-challenges-in-afghanestan/. Accessed September 27, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/inhibitors-in-hemophilia-treatment-challenges-in-afghanestan/